Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
20d
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 08, 2025--(BUSINESS ...
The program originated from a joint venture between the two companies that combined Rallybio’s expertise in HPP research with Recursion’s AI platform. Under the agreement, Rallybio will also receive ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results